Hyperandrogenemia and Altered Day-night LH Pulse Patterns
NCT03068910
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to determine if, in mid- to late pubertal girls with hyperandrogenism, androgen-receptor blockade (spironolactone) improves the ability of progesterone to acutely reduce waking luteinizing hormone pulse frequency (primary endpoint).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Hyperandrogenism
- Polycystic Ovary Syndrome
- Puberty
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Early Phase 1
- Ages
- 10 to 17 years
- Sex
- Female
- Healthy volunteers
- Accepted
- Sponsor
- University of Virginia
- Last updated on ClinicalTrials.gov
- August 5, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Virginia · 1
- University of Virginia Clinical Research Unit · Charlottesville, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.